Immunome/$IMNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunome
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Ticker
$IMNM
Sector
Primary listing
Employees
155
Headquarters
Website
Immunome Metrics
BasicAdvanced
$1.4B
-
-$2.94
1.93
-
Price and volume
Market cap
$1.4B
Beta
1.93
52-week high
$17.32
52-week low
$5.15
Average daily volume
1.5M
Financial strength
Current ratio
12.127
Quick ratio
11.716
Long term debt to equity
1.538
Total debt to equity
1.538
Profitability
EBITDA (TTM)
-188.419
Gross margin (TTM)
-954.77%
Net profit margin (TTM)
-1,687.08%
Operating margin (TTM)
-1,513.45%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-40.20%
Return on equity (TTM)
-81.20%
Valuation
Price to revenue (TTM)
92.4
Price to book
5.19
Price to tangible book (TTM)
5.19
Price to free cash flow (TTM)
-5.911
Free cash flow yield (TTM)
-16.92%
Free cash flow per share (TTM)
-2.718
Growth
Revenue change (TTM)
16.74%
Earnings per share change (TTM)
-53.45%
3-year earnings per share growth (CAGR)
-0.63%
What the Analysts think about Immunome
Analyst ratings (Buy, Hold, Sell) for Immunome stock.
Bulls say / Bears say
As of June 30, 2025, Immunome held $268.0 million in cash, cash equivalents and marketable securities, providing a runway into 2027 and reducing near-term dilution risk (Nasdaq cite)
Immunome recently dosed the third cohort in its Phase 1 trial of IM-1021, underscoring robust clinical execution and progress toward determining safety and preliminary efficacy of the ROR1-targeted ADC (Nasdaq cite)
The European Medicines Agency granted Orphan Drug Designation to varegacestat in July 2025, complementing prior U.S. orphan status and potentially expediting regulatory review with market exclusivity benefits (Nasdaq cite)
Net loss for Q2 2025 widened to $43.4 million from $36.1 million a year earlier, reflecting escalating operational costs and pressure on the company’s financial performance (Nasdaq cite)
Research and development expenses surged 39% year-over-year to $40.5 million in Q2 2025, increasing the company’s cash outflow and heightening reliance on successful clinical outcomes to stem the burn rate (Nasdaq cite)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Immunome Financial Performance
Revenues and expenses
Immunome Earnings Performance
Company profitability
Immunome News
AllArticlesVideos
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
Business Wire3 days ago
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
Business Wire2 weeks ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunome stock?
Immunome (IMNM) has a market cap of $1.4B as of November 03, 2025.
What is the P/E ratio for Immunome stock?
The price to earnings (P/E) ratio for Immunome (IMNM) stock is 0 as of November 03, 2025.
Does Immunome stock pay dividends?
No, Immunome (IMNM) stock does not pay dividends to its shareholders as of November 03, 2025.
When is the next Immunome dividend payment date?
Immunome (IMNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunome?
Immunome (IMNM) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.